TerminatedNCT03065933
An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-on, Open-Label Study
Medication studyAges 18–60Bipolarity
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJanuary 2012
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 5
- Sponsor
- Mclean Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT03065933
- Official title
Show the full official title
An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-On, Open-Label Study
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Questions about this study
Who is behind this study?
The study sponsor is Mclean Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including extended-release clonidine.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of Bipolarity type I